The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned?
Open accessAbstract
The pharmacokinetics (PK) of therapeutic antibodies is determined by target and non-target mediated mechanisms. These antibody-specific factors need to be considered during prediction of human PK based upon preclinical information. Principles of allometric scaling established for small molecules using data from multiple animal species cannot be directly applied to antibodies. Here, different methods for projecting human clearance (CL) from animal PK data for 13 therapeutic monoclonal antibodies (mAbs) exhibiting linear PK over the tested dose ranges were examined: simple allometric scaling (CL versus body weight), allometric scaling with correction factors, allometric scaling based on rule of exponent and scaling from only cynomolgus monkey PK data. A better correlation was obtained between the observed human CL and the estimated human CL based on cynomolgus monkey PK data and an allometric scaling exponent of 0.85 for CL than other scaling approaches. Human concentration-time profiles were also reasonably predicted from the cynomolgus monkey data using species-invariant time method with a fixed exponent of 0.85 for CL and 1.0 for volume of distribution. In conclusion, we expanded our previous work and others and further confirmed that PK from cynomolgus monkey alone can be successfully scaled to project human PK profiles within linear range using simplify allometry and Dedrick plots with fixed exponent.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Using this method, the volume of distribution scales proportionally with body weight and clearance often follows an exponent between 0.8–0.9 along with body weight scaling.66”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [66]
Citations
Cites
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,930
Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
Wang, W., Wang, E., & Balthasar, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.170 · Cited by 978
West, G. B., & Brown, J. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01589 · Cited by 806
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
Ober, R. J., Radu, C. G., Ghetie, V. F., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 502
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative Paradigm
Boxenbaum, H. G. (1984) · Drug Metabolism Reviews · doi:10.3109/03602538409033558 · Cited by 270
Interspecies Scaling: Predicting Clearance of Drugs in Humans. Three Different Approaches
Mahmood, I., & Balian, J. D. (1996) · Xenobiotica · doi:10.3109/00498259609052491 · Cited by 257
Lin, Y. S., Nguyen, C. B., Mendoza, J.-L., Escandón, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 256
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144
Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited
Wang, W., & Prueksaritanont, T. (2010) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.708 · Cited by 104
Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans
Mahmood, I. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10531 · Cited by 91
Pharmacokinetic Allometric Scaling of Antibodies: Application to the First-In-Human Dose Estimation
Mahmood, I. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21682 · Cited by 91
Tang, H., & Mayersohn, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20481 · Cited by 89
Kelley, S. K., Gelzleichter, T. R., Xie, D., Lee, W. P., Darbonne, W. C., Qureshi, F., Kissler, K. M., Oflazoglu, E., & Grewal, I. S. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706828 · Cited by 59
Kelley, S. K., Gelzleichter, T. R., Xie, D., Lee, W. P., Darbonne, W. C., Qureshi, F., Kissler, K. M., Oflazoglu, E., & Grewal, I. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707129 · Cited by 58
ACCURACY OF ALLOMETRICALLY PREDICTED PHARMACOKINETIC PARAMETERS IN HUMANS: ROLE OF SPECIES SELECTION
Tang, H., & Mayersohn, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004127 · Cited by 42
Vugmeyster, Y., Szklut, P., Tchistiakova, L., Abraham, W. M., Kasaian, M. T., & Xu, X. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2007.12.004 · Cited by 40
Kakkar, T., Ma, M., Yao, Z., Patton, A. K., Hu, Z., & Mounho, B. J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9316-2 · Cited by 37
Mahmood, I. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21597 · Cited by 30
Pharmacokinetic scaling of bisphenol A by species-invariant time methods
Cho, C. Y., Shin, B. S., Jung, J. H., Kim, D.-H., Lee, K. C., Han, S.-Y., Kim, H. S., Lee, B. M., & Yoo, S. D. (2002) · Xenobiotica · doi:10.1080/00498250210163315 · Cited by 22
Duconge-Soler, J., Fernández-Sánchez, E. M., & Alvarez, D. (2004) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.398 · Cited by 20
Flagged first, then by citations
Research works printed but not linked: 1
- Deng R, 2007, Prediction of human pharmacokinetics for monoclonal antibody
Cited by
Sorted by citations
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 780
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Jones, B. E., Brown‐Augsburger, P., Corbett, K. S., Westendorf, K., Davies, J., Cujec, T. P., Wiethoff, C. M., Blackbourne, J. L., Heinz, B. A., Foster, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf1906 · Cited by 546
Kitazawa, T., Igawa, T., Sampei, Z., Muto, A., Kojima, T., Soeda, T., Yoshihashi, K., Okuyama-Nishida, Y., Saito, H., Tsunoda, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2942 · Cited by 520
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liming, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 407
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Metadata
- Authors
- Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S.
- Affiliations
- Genentech (US)
- Corresponding author
- Deng, Rong
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2011-01
- Volume
- 3
- Issue
- 1
- Pages
- 61-66
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC3038012
- OpenAlex
- W1555185942
- Cited by
- 285
- References
- 24
- Citations by year
- 2026: 16 · 2025: 13 · 2024: 25 · 2023: 10 · 2022: 17 · 2021: 27 · 2020: 15 · 2019: 19 · 2018: 18 · 2017: 19 · 2016: 23 · 2015: 24 · 2014: 14 · 2013: 21 · 2012: 14
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- mAbs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- therapeutic monoclonal antibodies, human pharmacokinetics, allometric scaling, clearance prediction, Macaca fascicularis, volume of distribution
- MeSH terms
- Algorithms, Animals, Antibodies, Monoclonal, Drug Evaluation, Preclinical, Humans, Macaca fascicularis, Metabolic Clearance Rate, Models, Biological, Species Specificity, Mice, Rats, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
